Canaccord cuts DocGo stock price target on profitability concerns By Investing.com

DocGo reported Q4 2025 revenue of $74.9M, beating the $70.35M consensus (+6.47%), but EPS of -$1.37 missed the -$0.14 forecast (878.57% negative surprise); shares trade at $0.64, down ~77% over the past year. Canaccord cut its price target to $1.00 (from $1.50, Hold), Stifel trimmed its target to $2.50 (from $4.00, Buy), and Cantor Fitzgerald reiterated a $3.00 Overweight target. Management raised 2026 revenue and adjusted-EBITDA guidance ranges, targets adjusted-EBITDA profitability in H2 2026, and is pursuing strategic alternatives; recently acquired SteadyMD materially contributed to mobile health growth. Overall signals are mixed: solid revenue and guidance lift tempered by a large EPS miss, continued restructuring needs, and near-term valuation risk.

Analysis

DocGo’s situation is a classic mixed-optional-asset case: a stable, cash-generative transport franchise sitting next to a higher-volatility, scale-dependent Mobile Health growth engine. The transport side should act as a downside cushion for equity value while the SteadyMD/GLP-1 exposure creates asymmetric upside if the company can convert demand into repeatable, higher-margin recurring revenue.

Key near-term catalysts are corporate actions and the company’s cadence toward its mid‑2026 profitability target; a formal strategic‑alternatives process materially raises the chance of a valuation re‑rating within 3–6 months (asset sale, carve‑up or M&A). Material tail risks include a rapid normalization of GLP‑1 demand, payer pushback on remote prescribing models, or an inability to extract structural cost saves — any of which would push a recovery horizon beyond 12 months.

From a competitive-dynamics angle, successful scaling of at‑home GLP‑1 administration would force incumbents (regional EMS/ambulance contractors, some telehealth players) to either vertically integrate or concede lucrative care-management contracts, pressuring labor markets and subcontractor rates. The market appears to underweight the breakup optionality from separating the transport annuity from mobile-health upside, but also fairly discounts execution risk in scaling and margin improvement.

Key Decisions for Investors

• Event-driven small long: Buy DCGO equity sized to 0.5–1.0% of portfolio as a tactical position into the strategic-alternatives window (hold 3–6 months). Target a 2–3x equity pop on a process announcement or improved cadence; hard stop at -50% to cap loss given binary outcome.
• Option asymmetric: Buy Jan 2027 DCGO $2.50 calls (LEAP) as a lottery ticket (max 0.5% portfolio); expected holding period 12–18 months. Rationale: limited premium vs multi‑hundred percent upside if mobile-health scales or breakup occurs; accept total premium loss as downside.
• Hedged equity: If preferring a lower-volatility path, buy DCGO shares and simultaneously purchase a 6–9 month put ~30% OTM (cost-paid hedge) sized so net exposure = 0.5% portfolio. This preserves upside from a strategic process while capping immediate downside through the next two earnings releases.
• Risk-off trigger: Be ready to exit/short on two clear signals — (1) sequential contraction in core transport volumes, or (2) guidance retraction on 2026 profitability. Either should be treated as a >60% probability push of recovery beyond 12 months and warrants cutting exposure.